Vaxxas
June 17, 2025
Company Presentation
Infectious Disease and Vaccines
153A
Vaxxas' HD-MAP technology uses a patch with thousands of vaccine-coated microprojections that is applied to the skin via an applicator device, for seconds to efficiently deliver vaccine to the abundant immune cells immediately below the skin surface
Company HQ City:
Cambridge
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2012
Lead Product in Development:
Influenza vaccine on HD MAP
CEO
David Hoey
Development Phase of Lead Product
Phase I
What is your next catalyst (value inflection) update?
May 2025
Website
Www.vaxxas.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}